Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
66,577,393
-
Total 13F shares
-
18,710,542
-
Share change
-
+13,757,355
-
Total reported value
-
$265,500,071
-
Put/Call ratio
-
46%
-
Price per share
-
$14.19
-
Number of holders
-
63
-
Value change
-
+$207,902,213
-
Number of buys
-
53
-
Number of sells
-
10
Institutional Holders of Cardiff Oncology, Inc. - Common Stock (CRDF) as of Q3 2020
As of 30 Sep 2020,
Cardiff Oncology, Inc. - Common Stock (CRDF) was held by
63 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
18,710,542 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., CAXTON CORP, Opaleye Management Inc., VR Adviser, LLC, VANGUARD GROUP INC, JANUS HENDERSON GROUP PLC, FMR LLC, Corriente Advisors, LLC, Artal Group S.A., and PRICE T ROWE ASSOCIATES INC /MD/.
This page lists
63
institutional shareholders reporting positions in this security
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.